Fig. 1

Reduced expression of Claudin5 in ESCC tissues and its Association with Tumor Progression. A CLDN5 expression in pan-cancer using TIMER2.0 (http://timer.cistrome.org/), UALCAN (https://ualcan.path.uab.edu/), and GEPIA (http://gepia.cancer-pku.cn/) portals. B, C CLDN5 expression in normal and esophageal carcinoma (ESCA) tissues using GEPIA and UALCAN portals. D Representative images of immunohistochemical (IHC) staining of Claudin5 protein in adjacent normal (n = 42) and tumor tissues (n = 123) from collected ESCC patients samples. E Immunoreactivity score (IRS) of Claudin5 in 42 ESCC tumor tissues and paired adjacent normal tissues. F IRS of Claudin5 protein in adjacent normal (n = 42) and tumor tissues (n = 123) from collected ESCC patients samples. G IRS of Claudin5 protein in ESCC samples between patients with grade 3 (G3) tumors and grades 1–2 (G1–2). H IRS of Claudin5 protein in ESCC samples between patients with T1–2 stage and T3–4. I IRS of Claudin5 protein in ESCC samples between patients with node metastasis and patients without. The statistical difference was assessed with the unpaired nonparametric Mann–Whitney U test in E, F, G, H and I. *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001